Caterina Casari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6353687/publications.pdf

Version: 2024-02-01

36	871	430874	477307
papers	citations	18 h-index	29 g-index

36	36	36	1246
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Therapy, 2023, 30, 245-254.	4.5	11
2	A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient. Therapeutic Advances in Hematology, 2022, 13, 204062072210768.	2.5	0
3	Rasa3 deficiency minimally affects thrombopoiesis but promotes severe thrombocytopenia due to integrin-dependent platelet clearance. JCI Insight, 2022, 7, .	5.0	6
4	Towards novel treatment options in von Willebrand disease. Haemophilia, 2022, 28, 5-10.	2.1	6
5	Identification of von Willebrand factor D4 domain mutations in patients of Afroâ€Caribbean descent: In vitro characterization. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12737.	2.3	1
6	In vivo modulation of a dominantâ€negative variant in mouse models of von Willebrand disease type 2A. Journal of Thrombosis and Haemostasis, 2021, 19, 139-146.	3.8	5
7	A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization. Lab on A Chip, 2021, 21, 4791-4804.	6.0	14
8	Non-inhibitory antibodies inducing increased emicizumab clearance in a severe haemophilia A inhibitor patient. Haematologica, 2021, 106, 2287-2290.	3.5	10
9	Impact of the COVIDâ€19 pandemic on education and clinical training. Journal of Thrombosis and Haemostasis, 2021, 19, 2099-2100.	3.8	1
10	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	6.9	20
11	Camelidâ€derived singleâ€chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1087-1110.	2.3	8
12	A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood, 2020, 136, 740-748.	1.4	32
13	Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1843-1858.	2.4	19
14	A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. Thrombosis and Haemostasis, 2019, 119, 1981-1993.	3.4	5
15	von Willebrand Factor and Management of Heart Valve Disease. Journal of the American College of Cardiology, 2019, 73, 1078-1088.	2.8	37
16	Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica, 2018, 103, 728-737.	3.5	32
17	Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. Blood Advances, 2018, 2, 1417-1428.	5.2	9
18	A factor VIIIâ€“nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood, 2018, 132, 1193-1197.	1.4	19

#	Article	IF	Citations
19	Deletion of the Arp2/3 complex in megakaryocytes leads to microthrombocytopenia in mice. Blood Advances, 2017, 1, 1398-1408.	5.2	33
20	CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 792-799.	2.4	20
21	Acquired platelet disorders. Thrombosis Research, 2016, 141, S73-S75.	1.7	20
22	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. Scientific Reports, 2016, 6, 26306.	3.3	19
23	LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight, 2016, 1, e88643.	5.0	23
24	RASA3 is a critical inhibitor of RAP1-dependent platelet activation. Journal of Clinical Investigation, 2015, 125, 1419-1432.	8.2	113
25	Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. Blood, 2014, 123, 3344-3353.	1.4	6
26	VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013047.	1.3	3
27	Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood, 2013, 121, 2135-2143.	1.4	25
28	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2Bâ€“associated thrombocytopenia. Blood, 2013, 122, 2893-2902.	1.4	68
29	von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin Î±IIbÎ²3. Journal of Clinical Investigation, 2013, 123, 5071-5081.	8.2	42
30	Terminal Platelet Production is Regulated by Von Willebrand Factor. PLoS ONE, 2013, 8, e63810.	2.5	20
31	Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica, 2012, 97, 1855-1863.	3.5	70
32	Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood, 2012, 119, 2126-2134.	1.4	99
33	A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood, 2012, 120, 2723-2732.	1.4	16
34	Functional genetics. Thrombosis Research, 2012, 129, 336-340.	1.7	3
35	In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor. PLoS ONE, 2012, 7, e37508.	2.5	33
36	The dominant-negative von Willebrand factor gene deletion p.P1127_C1948delinsR: molecular mechanism and modulation. Blood, 2010, 116, 5371-5376.	1.4	23